FM
EGRX

Fondren Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Fondren Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-15,000
Closed -$604K – 105
2018
Q4 		$604K Buy
+15,000
New +$773K 0.79% 37
2017
Q4 		– Sell
-15,100
Closed -$901K – 61
2017
Q3 		$901K Buy
+15,100
New +$913K 0.72% 24

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fondren Management's EGRX Position: Q1 2019 in Review

Fondren Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2019, closing a stake of 15,000 shares — an estimated $604K sold.

Fondren Management first reported a position in EGRX in Q3 2017 and held it in 2 quarters. The position peaked at $901K in Q3 2017. 182 funds tracked by Wall St. Rank hold EGRX as of Q1 2019.

  • Fondren Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Fondren Management sold 15,000 Eagle Pharmaceuticals, Inc. shares in Q1 2019, an estimated $604K.
  • Fondren Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2017 and held it in 2 quarters.
  • Fondren Management's Eagle Pharmaceuticals, Inc. position peaked at $901K in Q3 2017.
  • 182 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2019.

Based on Fondren Management's 13F filing for Q1 2019, filed 15 May 2019.